Signet Laboratories, Inc.

Availability of polyclonal hepsin antibody announced

Published in Mental Health Law Weekly, December 17th, 2005

Signet Laboratories, Inc., a medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease, announced the availability of polyclonal hepsin antibody.

Hepsin is a cell surface serine protease upregulated in prostate cancer. The functional significance of this upregulation is unknown. Recent studies have reported that hepsin may play a role in the disorganization of the basement membrane and metastasis.

Improved screening and early diagnosis have reduced mortality, but the need exists for treatment options and prognostic markers for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Law Weekly

Source: Mental Health Law Weekly (2005-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry